This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer’s disease: a 26-week, open-label, prospective trial (Study ENA713B US32)


Olin, Jason T., Bhatnagar, Vinod, Reyes, Patricio, Koumaras, Barbara, Meng, Xiangyi, Brannan, Stephen


International Journal Of Geriatric Psychiatry, Volume: 25, No.: 4, Pages.: 419-426

Year of Publication



Objective: Rivastigmine, a dual cholinesterase inhibitor (ChEI), is widely approved for the symptomatic treatment of both mild-to-moderate Alzheimer’s disease (AD) and Parkinson’s disease dementia. Orally administered ChEIs may be associated with gastrointestinal (GI) side effects and add-on therapy with memantine, an N-methyl-d-aspartate receptor antagonist, approved for moderate-to-severe AD, may ameliorate such side effects. This was a 26-week, prospective, multicenter, single-arm, open-label pilot study to assess the safety and tolerability of rivastigmine capsules plus memantine in patients with moderate AD.; Methods: The primary objective was to assess the safety and tolerability of rivastigmine capsules 6-12 mg/day plus memantine (5-20 mg/day) as measured by the incidences of vomiting and nausea compared with those reported in the rivastigmine United States Prescribing Information (US PI). A total of 117 patients were enrolled with 116 receiving at least one dose of study medication.; Results: The incidences of nausea and vomiting (30% and 13%, respectively) observed in patients who received 6-12 mg/day rivastigmine plus memantine were lower than those stated in the US PI for rivastigmine monotherapy 6-12 mg/day (47% and 31%, respectively). The most common adverse events were nausea, vomiting, and dizziness.; Conclusion: Results from this study suggest the combination of rivastigmine capsule and memantine in patients with moderate AD is safe and tolerable. A greater reduction in the GI tolerability of rivastigmine has been established with rivastigmine transdermal patch.;

Bibtex Citation

@article{Olin_2010, doi = {10.1002/gps.2355}, url = {}, year = 2010, month = {apr}, publisher = {Wiley-Blackwell}, volume = {25}, number = {4}, pages = {419--426}, author = {Jason T. Olin and Vinod Bhatnagar and Patricio Reyes and Barbara Koumaras and Xiangyi Meng and Stephen Brannan}, title = {Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer{textquotesingle}s disease: a 26-week, open-label, prospective trial (Study {ENA}713B {US}32)}, journal = {Int. J. Geriat. Psychiatry} }


activities of daily living, administration oral, adverse effects, aged, aged, 80 and over, alzheimer disease, antiparkinson agents, blood pressure, capsules, cholinesterase inhibitors, cognition, dizziness, drug effects, drug therapy, drug therapy combination, epidemiology, excitatory amino acid antagonists, female, humans, incidence, male, medication, memantine, middle aged, nausea, phenylcarbamates, physiopathology, pilot projects, prospective studies, psychology, rivastigmine, therapeutic use, tolerability, vomiting

Countries of Study


Types of Dementia

Alzheimer’s Disease, Parkinson’s Dementia

Types of Study

Non randomised controlled trial

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime